| Basics |
Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical stage bio-pharmaceutical company. The Company is engaged in the developments drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, and various types of cancer.
|
| IPO Date: |
October 7, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$807.4M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.25 | 3.44%
|
| Avg Daily Range (30 D): |
$0.25 | 2.29%
|
| Avg Daily Range (90 D): |
$0.26 | 2.66%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.98M |
| Avg Daily Volume (30 D): |
.91M |
| Avg Daily Volume (90 D): |
.81M |
| Trade Size |
| Avg Trade Size (Sh.): |
152 |
| Avg Trade Size (Sh.) (30 D): |
89 |
| Avg Trade Size (Sh.) (90 D): |
89 |
| Institutional Trades |
| Total Inst.Trades: |
1,321 |
| Avg Inst. Trade: |
$1.49M |
| Avg Inst. Trade (30 D): |
$1.22M |
| Avg Inst. Trade (90 D): |
$1.3M |
| Avg Inst. Trade Volume: |
.15M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.57M |
| Avg Closing Trade (30 D): |
$1.13M |
| Avg Closing Trade (90 D): |
$1.23M |
| Avg Closing Volume: |
166.47K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.57
|
$-.16
|
$-.13
|
|
Diluted EPS
|
$-.57
|
$-.16
|
$-.13
|
|
Revenue
|
$ 5.44M
|
$ 1.08M
|
$ 1.21M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -48.17M
|
$ -13.24M
|
$ -11.2M
|
|
Operating Income / Loss
|
$ -54.84M
|
$ -14.46M
|
$ -12.51M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 07, 2015:
1:4
|
|
Jun 12, 2006:
6:1
|
|
|
|
